Adenosine deaminase severe combined immune deficiency (ADA-SCID) is an ultra-rare inherited, genetic disorder, caused by a deficiency in the adenosine deaminase (ADA) enzyme, that is often fatal if left untreated. ADA-SCID primarily affects infants and young children, whose compromised immune systems leave them unprotected from infection-producing bacteria, viruses, and fungi. Learn more about ADA-SCID including signs and symptoms, diagnosis, and treatment options.
For Healthcare Providers
Revcovi™ Ordering & Support
For information about ordering, please contact our partner, AllianceRx Walgreens Prime Specialty Pharmacy:
Patient Support Services
Navigating insurance coverage and reimbursement can be challenging for patients and healthcare providers. Some patients may be eligible for patient assistance programs or co-pay assistance programs. Leadiant Biosciences, Inc., offers patient support services through our partner, AllianceRx Walgreens Prime Specialty Pharmacy, to aid patients, caregivers, and healthcare providers with coverage and reimbursement concerns. Eligibility rules apply and are subject to change. Our partner also offers dedicated case managers for each patient who will support the patient immediately and over time, providing a broad range of services from disease education to finding access solutions to working with their insurance companies.
For more information about patient assistance or more information, contact AllianceRx Walgreens Prime Specialty Pharmacy at 1-877-534-9627.
Adverse Event Reporting
Information for Healthcare Professionals
Revcovi (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.
Important safety information
Warnings and precautions:
- Injection site bleeding in patients with thrombocytopenia: Increased risk of local bleeding in patients with thrombocytopenia; should not be used if thrombocytopenia is severe.
- Delay in improvement of immune function: Protect immune deficient patients from infections until improvement in immune function.
The most commonly reported adverse reactions were cough and vomiting.
In addition, the following post-marketing reports for the same class of enzyme replacement therapy used in the treatment of ADA-SCID, may also be seen with Revcovi treatment:
- Hematologic events: hemolytic anemia, autoimmune hemolytic anemia, thrombocythemia, thrombocytopenia and autoimmune thrombocytopenia
- Dermatological events: injection site erythema, urticaria
Important monitoring information:
Treatment with Revcovi should be monitored by measuring trough plasma ADA activity and trough dAXP levels for maintenance of therapeutic targets. If a persistent decline in plasma ADA activity occurs, immune function and clinical status should be monitored closely, and precautions should be taken to minimize the risk of infection.
Please refer to Revcovi’s Full Prescribing Information.